|1.||Lin, Shu: 2 articles (12/2013 - 01/2009)|
|2.||Sainsbury, Amanda: 2 articles (12/2013 - 01/2009)|
|3.||Shi, Yan-Chuan: 2 articles (12/2013 - 01/2009)|
|4.||Herzog, Herbert: 2 articles (12/2013 - 01/2009)|
|5.||Pedragosa-Badia, Xavier: 1 article (02/2014)|
|6.||Dong Nguyen, Elizabeth: 1 article (02/2014)|
|7.||Meiler, Jens: 1 article (02/2014)|
|8.||Sliwoski, Gregory R: 1 article (02/2014)|
|9.||Kaufmann, Kristian W: 1 article (02/2014)|
|10.||Stichel, Jan: 1 article (02/2014)|
09/01/2010 - "These findings indicate that the Y4 receptor and its agonist would be promising targets for obesity."
04/01/2009 - "The CNV contributed 1.6% of BMI variation, and it covered one important obesity gene-pancreatic polypeptide receptor 1(PPYR1). "
02/28/2014 - "Structural characterization of the human Y4 receptor (hY4R) interaction with human pancreatic polypeptide (hPP) is crucial, not only for understanding its biological function but also for testing treatment strategies for obesity that target this interaction. "
|2.||AIDS-Related Complex (ARC)
12/01/2013 - "PP activates preferably the lateral aspect of the Arc, the DMH, VMH, and LHA in a Y4 receptor-dependent manner. "
01/01/2009 - "These effects are a direct consequence of local Y4 signaling, since hypothalamus-specific conditional Y4 receptor knockout abolishes PP-induced ARC c-Fos activation and blocks the PP-induced increase in POMC mRNA expression. "
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
|1.||Messenger RNA (mRNA)
|3.||Pancreatic Polypeptide (Pancreatic Polypeptide (PP))
|5.||N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))